New drug trial for aggressive blood cancers ends early
Disease control
Terminated
This early-stage study tested a new drug called SGR-2921 in adults with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC